[PDF][PDF] FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor–expressing metastatic colorectal cancer patients …

WU Zhang, M Gordon, AM Schultheis… - Journal of clinical …, 2007 - researchgate.net
WU Zhang, M Gordon, AM Schultheis, DY Yang, F Nagashima, M Azuma, HM Chang…
Journal of clinical oncology, 2007researchgate.net
Purpose Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti–epidermal growth factor
receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with
metastatic colorectal cancer (CRC). Recent studies demonstrate antibody-dependent cell-
mediated cytotoxicity (ADCC) is one of the modes of action for rituximab and trastuzumab.
Fragment c (Fc) portion of IgG1 mAb has shown to induce ADCC. Fragment c gamma
receptors (FcR) play an important role in initiating ADCC. Studies have shown that two IgG …
Purpose
Cetuximab, a chimeric immunoglobulin G 1 (IgG1) anti–epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), has shown efficacy in 10% of patients with metastatic colorectal cancer (CRC). Recent studies demonstrate antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the modes of action for rituximab and trastuzumab. Fragment c (Fc) portion of IgG1 mAb has shown to induce ADCC. Fragment c gamma receptors (FcR) play an important role in initiating ADCC. Studies have shown that two IgG FcR polymorphisms (FCGR2A-H131R and FCGR3A-V158F) independently predict response to rituximab in patients with follicular lymphoma. We tested the hypothesis of whether these two polymorphisms are associated with clinical outcome in metastatic CRC patients treated with single-agent cetuximab.
researchgate.net